Orphan Drug Premium Long
In plain terms
A firm heuristic: long small biotechs (few Phase III programs) the day after a pivotal trial completion. Loosely motivated by the paper's rare-disease market-size idea, but the paper itself reports no stock-return premium; whether this carries alpha is tested empirically.
How it works
Firm heuristic loosely motivated by the market-size construct in Lichtenberg-Waldfogel (2003 NBER w9750). The paper establishes that the Orphan Drug Act spurred development for rare-disease (small-market) indications; it reports NO sponsor stock outperformance or holding period. We proxy the small-market idea with a small-sponsor screen (<=8 Phase III programs total) entering on a Phase III completion / results-first-posted event. Any equity edge is decided empirically, not asserted from the paper.
Data dependencies
- Daily prices
Adjusted-close OHLCV for every US-listed ticker; primary price feed.
- Clinical trials phaseiii
A data feed this strategy reads, refreshed on its normal schedule.
Expected edge
- Reported return
- n/a (paper has no equity finding)
- Tested over
- T+1 to T+120d
Empirically decided by the discovery harness; paper-unsupported. NBER w9750 is a health-economics study with no equity-return result, so no paper-backed premium is claimed.
Example tickers where this is likely to fire
Illustrative only, the signal fires based on the live data, not a fixed list.
Related families
When a drug company publicly posts the results of a late-stage (Phase III) trial, bet that its stock drifts down over the following weeks, and hold for about 2 to 8 weeks. The trade waits until the results are actually public before taking any position.
Buy a drug company's stock the day after one of its late-stage (Phase 3) trial results are posted publicly, and hold for 20, 40, or 60 trading days. This is our own event-study idea about post-announcement drift, not a finding from a research paper.
Explore Orphan Drug Premium Long on alphactor.ai
See which tickers this family is currently firing on, with live signals and rankings.